{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:06:50Z","timestamp":1789456010929,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Qingdao Key Clinical Specialty Elite Discipline"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05832-1","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:45:09Z","timestamp":1787831109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Lihua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-1857","authenticated-orcid":false,"given":"Wensheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"5832_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens V, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023.","journal-title":"Eur J Cancer"},{"issue":"10272","key":"5832_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(21)00153-7.","journal-title":"Lancet"},{"issue":"1","key":"5832_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","year":"2023","unstructured":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79(1):181\u2013208. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.010.","journal-title":"J Hepatol"},{"issue":"14","key":"5832_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"8","key":"5832_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"10391","key":"5832_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"6","key":"5832_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807. https:\/\/doi.org\/10.1016\/s1470-2045(20)30157-1.","journal-title":"Lancet Oncol"},{"issue":"6","key":"5832_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024;9(6):103488. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103488.","journal-title":"ESMO Open"},{"issue":"9","key":"5832_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/s1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234\u201343. https:\/\/doi.org\/10.1016\/s1470-2045(20)30321-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"5832_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2025.4736","volume":"12","author":"S Pant","year":"2026","unstructured":"Pant S, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Wasan H, Ducreux M, Bao Y, Wu X, Zhao Y, Garfin PM, Gable J, Harding JJ. Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01. JAMA Oncol. 2026;12(1):106\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2025.4736.","journal-title":"JAMA Oncol"},{"issue":"1","key":"5832_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA. Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/jco.19.02105.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5832_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20(7):470\u201386. https:\/\/doi.org\/10.1038\/s41571-023-00770-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"5832_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/s2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5832_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.2204","author":"DY Oh","year":"2026","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW. Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial. JAMA Oncol. 2026. https:\/\/doi.org\/10.1001\/jamaoncol.2026.2204.","journal-title":"JAMA Oncol"},{"issue":"16","key":"5832_CR15","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.Ccr-24-0517","volume":"30","author":"SJ Casak","year":"2024","unstructured":"Casak SJ, Kumar V, Song C, Yuan M, Amatya AK, Cheng J, Mishra-Kalyani PS, Tang S, Lemery SJ, Auth D, Davis G, Kluetz PG, Pazdur R, Fashoyin-Aje LA. FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clin Cancer Res. 2024;30(16):3371\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0517.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5832_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/s1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"5832_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"key":"5832_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/jco-26-00788","author":"TS Bekaii-Saab","year":"2026","unstructured":"Bekaii-Saab TS, Melisi D, Wilmink H, Garufi C, Tran N, Tortora G, et al. Pemigatinib for unresectable or metastatic cholangiocarcinoma with fibroblast growth factor receptor-2 rearrangement: results from the phase III FIGHT-302 trial. J Clin Oncol. 2026;44(23):2187\u201397 . https:\/\/doi.org\/10.1200\/jco-26-00788","journal-title":"J Clin Oncol"},{"issue":"5","key":"5832_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/1078-0432.Ccr-22-2036","volume":"29","author":"TH Patel","year":"2023","unstructured":"Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, et al. FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clin Cancer Res. 2023;29(5):838\u201342. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2036.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"5832_CR20","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol"},{"issue":"13","key":"5832_CR21","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1158\/1078-0432.Ccr-21-4462","volume":"28","author":"SJ Casak","year":"2022","unstructured":"Casak SJ, Pradhan S, Fashoyin-Aje LA, Ren Y, Shen YL, Xu Y, Chow ECY, Xiong Y, Zirklelbach JF, Liu J, Charlab R, Pierce WF, Fesenko N, Beaver JA, Pazdur R, Kluetz PG, Lemery SJ. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation. Clin Cancer Res. 2022;28(13):2733\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4462.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5832_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/s1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290\u2013300. https:\/\/doi.org\/10.1016\/s1470-2045(21)00336-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"5832_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s2468-1253(22)00335-1","volume":"8","author":"CK Lee","year":"2023","unstructured":"Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 2023;8(1):56\u201365. https:\/\/doi.org\/10.1016\/s2468-1253(22)00335-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"36","key":"5832_CR24","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/jco.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J Clin Oncol. 2023;41(36):5569\u201378. https:\/\/doi.org\/10.1200\/jco.23.00606.","journal-title":"J Clin Oncol"},{"issue":"27","key":"5832_CR25","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/jco.23.02010","volume":"42","author":"A Ohba","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol. 2024;42(27):3207\u201317. https:\/\/doi.org\/10.1200\/jco.23.02010.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5832_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00432-022-04485-1","volume":"149","author":"M He","year":"2023","unstructured":"He M, Jiang N, Yin X, Xu A, Mu K. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. J Cancer Res Clin Oncol. 2023;149(1):531\u201340. https:\/\/doi.org\/10.1007\/s00432-022-04485-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"5832_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.20452\/wiitm.2024.17906","volume":"19","author":"SR Pan","year":"2024","unstructured":"Pan SR, Wo XW, Zhu HF, Xia FF. Conventional and drug\u2013eluting bead transarterial chemoembolization in patients with inoperable intrahepatic cholangiocarcinoma: a meta\u2013analysis. Wideochir Inne Tech Maloinwazyjne. 2024;19(4):407\u201313. https:\/\/doi.org\/10.20452\/wiitm.2024.17906.","journal-title":"Wideochir Inne Tech Maloinwazyjne"},{"issue":"6","key":"5832_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","volume":"33","author":"DA Schartz","year":"2022","unstructured":"Schartz DA, Porter M, Schartz E, Kallas J, Gupta A, Butani D, Cantos A. Transarterial Yttrium-90 Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2022;33(6):679\u201386. https:\/\/doi.org\/10.1016\/j.jvir.2022.02.016.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"5832_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44(5):728\u201338. https:\/\/doi.org\/10.1007\/s00270-021-02800-w.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"5832_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, Boerner T, Tan BR, Chou JF, G\u00f6nen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D\u2019Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr., Kemeny NE, Jarnagin WR. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):60\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3718.","journal-title":"JAMA Oncol"},{"issue":"2","key":"5832_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/jnci\/djae202","volume":"117","author":"D Cowzer","year":"2025","unstructured":"Cowzer D, Soares K, Walch H, G\u00f6nen M, Boucher TM, Do RKG, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Connell LC, Abou-Alfa GK, Wei AC, Schultz N, Kingham TP, D\u2019Angelica MI, Drebin JA, Balachandran V, Sanchez-Vega F, Kemeny NE, Jarnagin WR, Cercek A. Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy. J Natl Cancer Inst. 2025;117(2):279\u201386. https:\/\/doi.org\/10.1093\/jnci\/djae202.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"5832_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/jco-25-00923","volume":"44","author":"S Franssen","year":"2026","unstructured":"Franssen S, Rousian M, Filipe WF, Buisman FE, Ten Haaft B, Swijnenburg RJ, et al. Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma-PUMP-2 trial. J Clin Oncol. 2026;44(6):455\u201365. https:\/\/doi.org\/10.1200\/jco-25-00923.","journal-title":"J Clin Oncol"},{"key":"5832_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.06.022","author":"M Rousian","year":"2026","unstructured":"Rousian M, Alessandris R, Schleimer L, Kalvin H, Zaki O, Connell L, Harding J, O\u2019Reilly E, Abou-Alfa G, Vachharajani N, Doyle M, Tan B, Khan A, Fields R, Franssen S, Filipe W, Buisman F, Mostert B, Homs M, Doukas M, Haaft BT, Swijnenburg RJ, Kl\u00fcmpen HJ, Hagendoorn J, Mohammad NH, D\u2019Amico FE, Soares K, Kingham P, Wei A, D\u2019Angelica M, G\u00f6nen M, Chapman W, Kemeny N, Cercek A, Jarnagin W, Koerkamp BG. Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials. J Hepatol. 2026. https:\/\/doi.org\/10.1016\/j.jhep.2026.06.022.","journal-title":"J Hepatol"},{"issue":"1","key":"5832_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09586-8","volume":"15","author":"L Liu","year":"2025","unstructured":"Liu L, Wang H, Sun L, Liu Y, Zhang Y, Wang X, et al. Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma. Sci Rep. 2025;15(1):21588. https:\/\/doi.org\/10.1038\/s41598-025-09586-8.","journal-title":"Sci Rep"},{"issue":"1","key":"5832_CR35","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1097\/js9.0000000000002013","volume":"111","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, Wang J, Wu T, He M, Pan Y, Wang J, Chen J, Hu D, Xu L, Zhang Y, Chen M, Zhou Z. Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study. Int J Surg. 2025;111(1):1552\u20137. https:\/\/doi.org\/10.1097\/js9.0000000000002013.","journal-title":"Int J Surg"},{"issue":"1","key":"5832_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12916-024-03381-4","volume":"22","author":"M Zhu","year":"2024","unstructured":"Zhu M, Jin M, Zhao X, Shen S, Chen Y, Xiao H, Wei G, He Q, Li B, Peng Z. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024;22(1):165. https:\/\/doi.org\/10.1186\/s12916-024-03381-4.","journal-title":"BMC Med"},{"issue":"2","key":"5832_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00330-021-08216-x","volume":"32","author":"GH Kim","year":"2022","unstructured":"Kim GH, Kim PH, Kim JH, Kim PN, Won HJ, Shin YM, et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol. 2022;32(2):1205\u201315. https:\/\/doi.org\/10.1007\/s00330-021-08216-x.","journal-title":"Eur Radiol"},{"issue":"1","key":"5832_CR38","doi-asserted-by":"publisher","first-page":"760","DOI":"10.21037\/qims-24-607","volume":"15","author":"M Song","year":"2025","unstructured":"Song M, Li J, Li Y, Zhang C, Sigdel M, Hou R, Jiao D, Zhou X. Efficacy of microwave ablation for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Quant Imaging Med Surg. 2025;15(1):760\u20139. https:\/\/doi.org\/10.21037\/qims-24-607.","journal-title":"Quant Imaging Med Surg"},{"key":"5832_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102336","volume":"67","author":"C Pang","year":"2024","unstructured":"Pang C, Li J, Dou J, Li Z, Li L, Li K, et al. Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study. EClinicalMedicine. 2024;67:102336. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102336.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"5832_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s43018-025-01058-2","volume":"7","author":"S Gu","year":"2026","unstructured":"Gu S, Luo Q, Zhang Y, Qian L, Chen K, Liang F, Hu Y, Zhou R, Wang Y, Liu J, Ning Z, Xu L, Meng Z, Li Y, Wang P. Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial. Nat Cancer. 2026;7(1):60\u201379. https:\/\/doi.org\/10.1038\/s43018-025-01058-2.","journal-title":"Nat Cancer"},{"issue":"9","key":"5832_CR41","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1109\/tuffc.2021.3073563","volume":"68","author":"A Hendricks-Wenger","year":"2021","unstructured":"Hendricks-Wenger A, Weber P, Simon A, Saunier S, Coutermarsh-Ott S, Grider D, et al. Histotripsy for the treatment of cholangiocarcinoma liver tumors: in vivo feasibility and ex vivo dosimetry study. IEEE Trans Ultrason Ferroelectr Freq Control. 2021;68(9):2953\u201364. https:\/\/doi.org\/10.1109\/tuffc.2021.3073563.","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"issue":"2","key":"5832_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ultrasmedbio.2021.10.002","volume":"48","author":"A Hendricks-Wenger","year":"2022","unstructured":"Hendricks-Wenger A, Saunier S, Simon A, Grider D, Luyimbazi D, Allen IC, et al. Histotripsy for the treatment of cholangiocarcinoma in a patient-derived xenograft mouse model. Ultrasound Med Biol. 2022;48(2):293\u2013303. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2021.10.002.","journal-title":"Ultrasound Med Biol"},{"key":"5832_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2018.07.010","volume":"102","author":"CY Huang","year":"2018","unstructured":"Huang CY, Hsieh FS, Wang CY, Chen LJ, Chang SS, Tsai MH, Hung MH, Kuo CW, Shih CT, Chao TI, Chen KF. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer. 2018;102:10\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.010.","journal-title":"Eur J Cancer"},{"issue":"4","key":"5832_CR44","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/cam4.1318","volume":"7","author":"Y Mao","year":"2018","unstructured":"Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, et al. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. Cancer Med. 2018;7(4):1285\u201396. https:\/\/doi.org\/10.1002\/cam4.1318.","journal-title":"Cancer Med"},{"issue":"3","key":"5832_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/sj.cgt.7700890","volume":"13","author":"WR Jarnagin","year":"2006","unstructured":"Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, et al. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 2006;13(3):326\u201334. https:\/\/doi.org\/10.1038\/sj.cgt.7700890.","journal-title":"Cancer Gene Ther"},{"key":"5832_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.biomaterials.2018.08.052","volume":"183","author":"DH Kim","year":"2018","unstructured":"Kim DH, Im BN, Hwang HS, Na K. Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials. 2018;183:139\u201350. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.08.052.","journal-title":"Biomaterials"},{"key":"5832_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.723488","volume":"12","author":"YW Zheng","year":"2021","unstructured":"Zheng YW, Miao XY, Xiong L, Chen B, Kong FH, Zhou JJ, et al. Sulfasalazine sensitizes polyhematoporphyrin-mediated photodynamic therapy in cholangiocarcinoma by targeting xCT. Front Pharmacol. 2021;12:723488. https:\/\/doi.org\/10.3389\/fphar.2021.723488.","journal-title":"Front Pharmacol"},{"key":"5832_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1288255","volume":"15","author":"YP Huang","year":"2024","unstructured":"Huang YP, Wang YX, Zhou H, Liu ZT, Zhang ZJ, Xiong L, et al. Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinoma in vitro and in tumor models. Front Pharmacol. 2024;15:1288255. https:\/\/doi.org\/10.3389\/fphar.2024.1288255.","journal-title":"Front Pharmacol"},{"issue":"12","key":"5832_CR49","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.jvir.2015.06.032","volume":"26","author":"J Edeline","year":"2015","unstructured":"Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Cl\u00e9ment B, Garin E. Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. J Vasc Interv Radiol. 2015;26(12):1874\u201378.e2. https:\/\/doi.org\/10.1016\/j.jvir.2015.06.032","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"5832_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2026.107994","volume":"37","author":"J Wu","year":"2026","unstructured":"Wu J, Liang Y, Ren Y, Yuan B, Hu H, Zhang Z, et al. Effect of transarterial embolization combined with chemotherapy on regulatory T cells and vascular endothelial growth factor in the tumor immune microenvironment of intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2026;37(4):107994. https:\/\/doi.org\/10.1016\/j.jvir.2026.107994.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"5832_CR51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1148\/radiol.13130866","volume":"270","author":"F Zhang","year":"2014","unstructured":"Zhang F, Le T, Wu X, Wang H, Zhang T, Meng Y, et al. Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging\u2013preclinical study. Radiology. 2014;270(2):400\u20138. https:\/\/doi.org\/10.1148\/radiol.13130866.","journal-title":"Radiology"},{"issue":"47","key":"5832_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202508101","volume":"37","author":"R Zhang","year":"2025","unstructured":"Zhang R, Yang W, Zhou Z, Ding M, Wang H, Yuan W, et al. Ultrasound-activated piezoelectric nanoparticles targeting and activating NK cells for tumor immunotherapy. Adv Mater. 2025;37(47):e08101. https:\/\/doi.org\/10.1002\/adma.202508101.","journal-title":"Adv Mater"},{"issue":"14","key":"5832_CR53","doi-asserted-by":"publisher","first-page":"e2307143","DOI":"10.1002\/advs.202307143","volume":"11","author":"W Wang","year":"2024","unstructured":"Wang W, Gao Y, Xu J, Zou T, Yang B, Hu S, Cheng X, Xia Y, Zheng Q. A NRF2 Regulated and the Immunosuppressive Microenvironment Reversed Nanoplatform for Cholangiocarcinoma Photodynamic-Gas Therapy. Adv Sci (Weinh). 2024;11(14):e2307143. https:\/\/doi.org\/10.1002\/advs.202307143.","journal-title":"Adv Sci (Weinh)"},{"issue":"29","key":"5832_CR54","doi-asserted-by":"publisher","first-page":"e2309203","DOI":"10.1002\/advs.202309203","volume":"11","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, Zou T, Wang W, Zhang C, Hu S, Cheng X, Liu R, Wang G, Sun P, Zhou X, Yang B, Xu J, Gao Y, Gu J. Necroptosis-Mediated Synergistic Photodynamic and Glutamine-Metabolic Therapy Enabled by a Biomimetic Targeting Nanosystem for Cholangiocarcinoma. Adv Sci (Weinh). 2024;11(29):e2309203. https:\/\/doi.org\/10.1002\/advs.202309203.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"5832_CR55","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/cas.14780","volume":"112","author":"H Hirata","year":"2021","unstructured":"Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, et al. Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes. Cancer Sci. 2021;112(2):828\u201338. https:\/\/doi.org\/10.1111\/cas.14780.","journal-title":"Cancer Sci"},{"issue":"6","key":"5832_CR56","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.Ccr-17-0432","volume":"24","author":"Y Guo","year":"2018","unstructured":"Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, Wang Y, Jia H, Han W. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clin Cancer Res. 2018;24(6):1277\u201386. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0432.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5832_CR57","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","volume":"9","author":"K Feng","year":"2018","unstructured":"Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838\u201347. https:\/\/doi.org\/10.1007\/s13238-017-0440-4.","journal-title":"Protein Cell"},{"issue":"2","key":"5832_CR58","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcyt.2022.10.006","volume":"25","author":"K Supimon","year":"2023","unstructured":"Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy. 2023;25(2):148\u201361. https:\/\/doi.org\/10.1016\/j.jcyt.2022.10.006.","journal-title":"Cytotherapy"},{"key":"5832_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-026-03723-5","author":"S Arya","year":"2026","unstructured":"Arya S, Ventin M, Cattaneo G, Nebbia M, Sanatkar SA, Martin C, et al. B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response. J Exp Clin Cancer Res. 2026;45(1):131 . https:\/\/doi.org\/10.1186\/s13046-026-03723-5","journal-title":"J Exp Clin Cancer Res"},{"key":"5832_CR60","doi-asserted-by":"publisher","unstructured":"Duangdara J, Lin S, Hong J, Li D, Suriyonplengsaeng C, Larbcharoensub N, Wongprasert K, Ho M. Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinoma. Hepatol Commun. 2026;10(2):e0888 . https:\/\/doi.org\/10.1097\/hc9.0000000000000888","DOI":"10.1097\/hc9.0000000000000888"},{"key":"5832_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-49988-w","author":"N Khuisangeam","year":"2026","unstructured":"Khuisangeam N, Chinsuwan T, Intanachai T, Thaiwong R, Boonkrai C, Phakham T, et al. MUC1-targeted CAR-T cell secreted anti-PD-1 IgG antibody enhances antitumor activity in cholangiocarcinoma. Sci Rep. 2026;16(1):18597 . https:\/\/doi.org\/10.1038\/s41598-026-49988-w","journal-title":"Sci Rep"},{"issue":"2","key":"5832_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201209","volume":"34","author":"P Gondaliya","year":"2026","unstructured":"Gondaliya P, Luo Y, Sayyed AA, Zinn DA, Qie Y, Yan IK, et al. CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: a proof of concept study. Mol Ther Oncol. 2026;34(2):201209. https:\/\/doi.org\/10.1016\/j.omton.2026.201209.","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"5832_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol"},{"issue":"1","key":"5832_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/hep.0000000000000544","volume":"79","author":"J Edeline","year":"2024","unstructured":"Edeline J, Bridgewater J, Campillo-Gimenez B, Neveu E, Phelip JM, Neuzillet C, et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials. Hepatology. 2024;79(1):96\u2013106. https:\/\/doi.org\/10.1097\/hep.0000000000000544.","journal-title":"Hepatology"},{"issue":"9","key":"5832_CR65","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","volume":"29","author":"RCG Martin","year":"2022","unstructured":"Martin RCG 2nd, Simo KA, Hansen P, Rocha F, Philips P, McMasters KM, et al. Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin. Ann Surg Oncol. 2022;29(9):5462\u201373. https:\/\/doi.org\/10.1245\/s10434-022-11932-3.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"5832_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00262-025-04129-6","volume":"74","author":"S Li","year":"2025","unstructured":"Li S, Yu G, Wang M, Feng S, Zhang A, Wu Y, Zhou Z, Wang S, Zhang Y, Piao M, Li C, Xun Z, Sun B, Li J, Zhang N, Li H, Sun Y, Zhang W, Zhu Z, Zhao H. Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunol Immunother. 2025;74(8):271. https:\/\/doi.org\/10.1007\/s00262-025-04129-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"5832_CR67","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/meg.0000000000003141","volume":"38","author":"L Bian","year":"2026","unstructured":"Bian L, Luo L, Kang G, Liu Y, Yang J. Safety evaluation of drug-eluting bead transarterial chemoembolization in combination with immune checkpoint inhibitors in the treatment of unresectable intrahepatic cholangiocarcinoma: risk factors for liver abscess. Eur J Gastroenterol Hepatol. 2026;38(5):608\u201314. https:\/\/doi.org\/10.1097\/meg.0000000000003141.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5832_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1435639","volume":"15","author":"KS Li","year":"2024","unstructured":"Li KS, Liu Y, Zhang TZ, Xu YF, Zhang ZL. Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma. Front Pharmacol. 2024;15:1435639. https:\/\/doi.org\/10.3389\/fphar.2024.1435639.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5832_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jvir.2021.09.012","volume":"33","author":"T Zhang","year":"2022","unstructured":"Zhang T, Chen J, Niu L, Liu Y, Ye G, Jiang M, Qi Z. Clinical Safety and Efficacy of Locoregional Therapy Combined with Adoptive Transfer of Allogeneic \u03b3\u03b4 T Cells for Advanced Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2022;33(1):19\u201327.e3 . https:\/\/doi.org\/10.1016\/j.jvir.2021.09.012","journal-title":"J Vasc Interv Radiol"},{"issue":"14","key":"5832_CR70","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.Ccr-21-0412","volume":"27","author":"JS Jolissaint","year":"2021","unstructured":"Jolissaint JS, Soares KC, Seier KP, Kundra R, G\u00f6nen M, Shin PJ, Boerner T, Sigel C, Madupuri R, Vakiani E, Cercek A, Harding JJ, Kemeny NE, Connell LC, Balachandran VP, D\u2019Angelica MI, Drebin JA, Kingham TP, Wei AC, Jarnagin WR. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clin Cancer Res. 2021;27(14):4101\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0412.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5832_CR71","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/lvt.0000000000000589","volume":"31","author":"S Kodali","year":"2025","unstructured":"Kodali S, Kulik L, D\u2019Allessio A, De Martin E, Hakeem AR, Lewinska M, Lindsey S, Liu K, Maravic Z, Patel MS, Pinato D, Rammohan A, Rich N, Sanduzzi Zamparelli M, Victor DW 3rd, Vinaxia C, Brombosz EW, Villanueva A, Meyer T, Selzner N, Ghobrial RM, Rela M, Sapisochin G. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma. Liver Transpl. 2025;31(6):815\u201331. https:\/\/doi.org\/10.1097\/lvt.0000000000000589.","journal-title":"Liver Transpl"},{"issue":"4","key":"5832_CR72","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/hep.28744","volume":"64","author":"G Sapisochin","year":"2016","unstructured":"Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J. Liver transplantation for very early intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178\u201388. https:\/\/doi.org\/10.1002\/hep.28744.","journal-title":"Hepatology"},{"issue":"5","key":"5832_CR73","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s2468-1253(18)30045-1","volume":"3","author":"KE Lunsford","year":"2018","unstructured":"Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3(5):337\u201348. https:\/\/doi.org\/10.1016\/s2468-1253(18)30045-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"5832_CR74","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ajt.16906","volume":"22","author":"RR McMillan","year":"2022","unstructured":"McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022;22(3):823\u201332. https:\/\/doi.org\/10.1111\/ajt.16906.","journal-title":"Am J Transplant"},{"key":"5832_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13641","volume":"37","author":"M Maspero","year":"2024","unstructured":"Maspero M, Sposito C, Bongini MA, Cascella T, Flores M, Maccauro M, et al. Liver transplantation for intrahepatic cholangiocarcinoma after chemotherapy and radioembolization: an intention-to-treat study. Transpl Int. 2024;37:13641. https:\/\/doi.org\/10.3389\/ti.2024.13641.","journal-title":"Transpl Int"},{"key":"5832_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf054","author":"S Yaqub","year":"2025","unstructured":"Yaqub S, Busund S, Smedman TM, Syversveen T, Khan A, Solheim JM, et al. Liver transplantation for locally advanced non-resectable intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: early results from the TESLA trial. Br J Surg. 2025;112(3):znaf054 . https:\/\/doi.org\/10.1093\/bjs\/znaf054","journal-title":"Br J Surg"},{"issue":"7","key":"5832_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101830","volume":"8","author":"B Giguet","year":"2026","unstructured":"Giguet B, Artru F, Jeddou H, Houssel-Debry P, Jegonday MA, Coirier V, et al. Liver transplantation in unresectable intrahepatic cholangiocarcinoma following neoadjuvant chemotherapy and SIRT. JHEP Rep. 2026;8(7):101830. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101830.","journal-title":"JHEP Rep"},{"key":"5832_CR78","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001686","author":"A Saborowski","year":"2026","unstructured":"Saborowski A, Simon P, Zhao J, Marhenke S, Volk V, Reschke JS, Korosteleva A, Yi D, Reineke-Plaa\u00df T, Augustin J, Tran DDH, Ibarra-Arellano MA, Schapiro D, Lemke S, Kr\u00f6nke N, Rapposelli IG, Segatto O, Bathon M, Gerdes C, Calderaro J, Kolch W, Zhernovkov V, Feuerhake F, Vogel A. Stroma-driven intertumoral and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation. Hepatology. 2026. https:\/\/doi.org\/10.1097\/hep.0000000000001686.","journal-title":"Hepatology"},{"issue":"10","key":"5832_CR79","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"5832_CR80","doi-asserted-by":"publisher","first-page":"e2200003","DOI":"10.1200\/po.22.00003","volume":"6","author":"SS Liddell","year":"2022","unstructured":"Liddell SS, Chakrabarti S, Wintheiser GA, Zemla TJ, Shi Q, Tella SH, Jin Z, Wookey VB, Hassan H, Tran NH, Borad MJ, Mahipal A. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precis Oncol. 2022;6:e2200003. https:\/\/doi.org\/10.1200\/po.22.00003.","journal-title":"JCO Precis Oncol"},{"key":"5832_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010173","author":"SY Chung","year":"2025","unstructured":"Chung SY, Yeh YC, Huang CJ, Chiang NJ, Hsu DS, Chan MH, et al. Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma. J Immunother Cancer. 2025;13(1):e010173 . https:\/\/doi.org\/10.1136\/jitc-2024-010173","journal-title":"J Immunother Cancer"},{"issue":"20","key":"5832_CR82","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1158\/1078-0432.Ccr-24-1265","volume":"30","author":"YH Bang","year":"2024","unstructured":"Bang YH, Lee CK, Bang K, Kim HD, Kim KP, Jeong JH, Park I, Ryoo BY, Lee DK, Choi HJ, Chung T, Jeon SH, Shin EC, Oum C, Kim S, Lim Y, Park G, Ahn CH, Lee T, Finn RS, Ock CY, Shin J, Yoo C. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer. Clin Cancer Res. 2024;30(20):4635\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1265.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5832_CR83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","volume":"15","author":"T Xia","year":"2022","unstructured":"Xia T, Li K, Niu N, Shao Y, Ding D, Thomas DL, Jing H, Fujiwara K, Hu H, Osipov A, Yuan C, Wolfgang CL, Thompson ED, Anders RA, He J, Mou Y, Murphy AG, Zheng L. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J Hematol Oncol. 2022;15(1):37. https:\/\/doi.org\/10.1186\/s13045-022-01253-z.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"5832_CR84","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jhep.2022.05.043","volume":"77","author":"G Alvisi","year":"2022","unstructured":"Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, et al. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. J Hepatol. 2022;77(5):1359\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.043.","journal-title":"J Hepatol"},{"issue":"4","key":"5832_CR85","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang S, Woo S, Kang B, Kang H, Kim JS, Lee SH, Kwon CI, Kyung DS, Kim HP, Kim G, Kim C, Chon HJ. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol. 2025;82(4):649\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.020.","journal-title":"J Hepatol"},{"key":"5832_CR86","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00443","volume":"9","author":"J Yu","year":"2025","unstructured":"Yu J, He AR, Ouf M, Mehta R, Anaya DA, Denbo J, et al. Detecting early recurrence with circulating tumor DNA in stage I-III biliary tract cancer after curative resection. JCO Precis Oncol. 2025;9:e2400443. https:\/\/doi.org\/10.1200\/po-24-00443.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"5832_CR87","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jhep.2024.02.008","volume":"80","author":"JL Tomlinson","year":"2024","unstructured":"Tomlinson JL, Li B, Yang J, Loeuillard E, Stumpf HE, Kuipers H, Watkins R, Carlson DM, Willhite J, O\u2019Brien DR, Graham RP, Chen X, Smoot RL, Dong H, Gores GJ, Ilyas SI. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. J Hepatol. 2024;80(6):892\u2013903. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.008.","journal-title":"J Hepatol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05832-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:17:24Z","timestamp":1789453044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5832"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05832-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1332"}}